US2004018237A1PendingUtilityA1

Topical drug delivery using phosphatidylcholine

59
Priority: May 31, 2002Filed: May 30, 2003Published: Jan 29, 2004
Est. expiryMay 31, 2022(expired)· nominal 20-yr term from priority
Inventors:Nicholas V. Perricone
A61P 3/10A61P 5/06A61K 9/06A61K 38/27A61J 3/07A61K 9/0014A61K 38/02A61K 38/31A61K 38/28A61P 17/00A61K 47/34A61K 9/02A61K 38/095A61K 47/14A61K 47/24A61K 9/1277A61K 38/24C07K 14/62A61K 31/56A61K 38/56A61K 47/22A61K 9/127A61K 47/10A61K 38/23
59
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention relates to compositions and methods for transdermal drug delivery comprising formulating a phosphatidylcholine carrier composition containing the drug and applying the composition to the skin.

Claims

exact text as granted — not AI-modified
What is claimed is:  
     
         1 . A composition comprising crystallized phosphatidylcholine and drug molecules entrapped within said phosphatidylcholine.  
     
     
         2 . A composition of  claim 1 , wherein the drug molecules comprise polypeptides.  
     
     
         3 . The composition of  claim 1  wherein the drug molecules are selected from the group consisting of oxytocin, vasopressin, insulin, somatotropin, calcitonin, chorionic gonadotropin, menotropins, follitropins, somatostatins, progestins, and combinations of any of these.  
     
     
         4 . The composition of  claim 1  wherein the composition contains about 85% phosphatidylcholine.  
     
     
         5 . The composition of  claim 1  wherein the phosphatidylcholine is soybean lecithin.  
     
     
         6 . The composition of  claim 1 ,  2 ,  3 , or  4  further comprising polyenylphosphatidylcholine.  
     
     
         7 . The composition of claims  1 ,  2 ,  3 ,  4  or  5  further comprising one or more of ascorbyl palmitate and lipoic acid.  
     
     
         8 . A method for topically administering a macromolecular drug comprising formulating a composition containing the drug in a non-polar or crystal phosphatidylcholine carrier and applying the composition to the skin.  
     
     
         9 . A method according to  claim 8  wherein the composition contains about 85% phosphatidylcholine.  
     
     
         10 . A method according to claims  8  or  9  wherein the phosphatidylcholine is soybean lecithin.  
     
     
         11 . A method according to claims  8 ,  9 , or  10  wherein the phosphatidylcholine contains polyenylphosphatidylcholine.  
     
     
         12 . A method according to  claim 8  wherein the macromolecular drug is a polypeptide.  
     
     
         13 . A method according to  claim 12  wherein the polypeptide is selected from the group consisting of oxytocin, vasopressin, insulin, somatotropin, calcitonin, chorionic gonadotropin, menotropins, follitropins, somatostatins, progestins, and combinations of any of these.  
     
     
         14 . A method according to  claim 12  wherein the polypeptide is somatotropin.  
     
     
         15 . A method according to  claim 12  wherein the polypeptide is insulin.  
     
     
         16 . A method for administering insulin to a patient comprising topically applying a composition comprising a crystal or non-polar phosphatidylcholine carrier and insulin to skin of the patient.  
     
     
         17 . The method of  claim 16 , wherein the phosphatidylcholine carrier comprises about 85% phosphatidylcholine.  
     
     
         18 . A method according to claims  17  wherein the phosphatidylcholine carrier contains polyenylphosphatidylcholine.

Join the waitlist — get patent alerts

Track US2004018237A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.